Hartmann Group sales up 3.5% in FY’2012
April 01, 2013 - Germany
With a sales increase of 3.5%, the HARTMANN GROUP continued on its previous years’ growth path in fiscal year 2012 and again achieved record sales with EUR 1,758 million. With a situation characterized by spending cuts in the national health care systems, EBIT from regular business increased by 2.5% to EUR 110.2 million despite higher investments in marketing and sales capacities.
HARTMANN Increased consolidated sales in a difficult environment
In the Wound Management Segment, HARTMANN recorded 3.9% growth to EUR 473.5 million in 2012. Within the strong product ranges, HARTMANN again achieved above-market growth in modern wound care products and postoperative dressings. Products for compression therapy were well received by customers. Sales of Vivano, the negative-pressure wound therapy system, developed worldwide positively in 2012 in the first full fiscal year since the market launch.
The business with traditional dressing materials was negatively impacted due to recall of some gauze products. The pharmacy business with medical products for consumers developed positively, particularly in the first-aid and clinical thermometer categories.
With sales revenues of EUR 629.5 million, the Incontinence Management segment was again the largest segment. The structural share was 35.8% and therefore almost at the previous year's level. Growth was 3.0% compared to the previous year. In 2012, HARTMANN again benefited from good growth in MoliCare Mobile incontinence pants, used especially by mobile people.
Not least because of the increasing cost pressure, the company sees a trend to switch from one-piece to two-piece product systems. Pads offered under the MoliForm brand, which are applied together with a fixation system such as MoliPants, profited from this. The Menalind professional skin-care range designed for the skin of elderly people was also well received by customers in the year under review.
In the Infection Management segment, Group-wide sales revenues increased by 1.9% to EUR 378.6 million in 2012. Related to the product range for holistic infection prevention, customized surgical sets under the Foliodrape CombiSet brand delivered good growth. In addition to continued good development in hand disinfectants, HARTMANN further strengthened its market position in the field of surface disinfection in the year under review.
The range of disposable surgical instruments was highly appreciated in hospitals and outpatient surgical facilities. Due to a recall action, sales for some medical products for the operating theater declined in fiscal year 2012. In examination gloves, HARTMANN refrained from sales in favor of profitability.
In the three medical core segments Wound Management, Incontinence Management and Infection Management, sales revenues rose by 3.0% to EUR 1,481.6 million. The share of the medical core business was 84.3% in 2012 and remained at the previous year’s level.
In Other Group Activities, which include consumer products and trading activities, HARTMANN recorded sales revenues of EUR 276.8 million, an increase of 6.0%.
HARTMANN Increased consolidated sales in a difficult environment
In the Wound Management Segment, HARTMANN recorded 3.9% growth to EUR 473.5 million in 2012. Within the strong product ranges, HARTMANN again achieved above-market growth in modern wound care products and postoperative dressings. Products for compression therapy were well received by customers. Sales of Vivano, the negative-pressure wound therapy system, developed worldwide positively in 2012 in the first full fiscal year since the market launch.
The business with traditional dressing materials was negatively impacted due to recall of some gauze products. The pharmacy business with medical products for consumers developed positively, particularly in the first-aid and clinical thermometer categories.
With sales revenues of EUR 629.5 million, the Incontinence Management segment was again the largest segment. The structural share was 35.8% and therefore almost at the previous year's level. Growth was 3.0% compared to the previous year. In 2012, HARTMANN again benefited from good growth in MoliCare Mobile incontinence pants, used especially by mobile people.
Not least because of the increasing cost pressure, the company sees a trend to switch from one-piece to two-piece product systems. Pads offered under the MoliForm brand, which are applied together with a fixation system such as MoliPants, profited from this. The Menalind professional skin-care range designed for the skin of elderly people was also well received by customers in the year under review.
In the Infection Management segment, Group-wide sales revenues increased by 1.9% to EUR 378.6 million in 2012. Related to the product range for holistic infection prevention, customized surgical sets under the Foliodrape CombiSet brand delivered good growth. In addition to continued good development in hand disinfectants, HARTMANN further strengthened its market position in the field of surface disinfection in the year under review.
The range of disposable surgical instruments was highly appreciated in hospitals and outpatient surgical facilities. Due to a recall action, sales for some medical products for the operating theater declined in fiscal year 2012. In examination gloves, HARTMANN refrained from sales in favor of profitability.
In the three medical core segments Wound Management, Incontinence Management and Infection Management, sales revenues rose by 3.0% to EUR 1,481.6 million. The share of the medical core business was 84.3% in 2012 and remained at the previous year’s level.
In Other Group Activities, which include consumer products and trading activities, HARTMANN recorded sales revenues of EUR 276.8 million, an increase of 6.0%.